---
title: "Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program | SNTI Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286418645.md"
description: "Senti Biosciences Holdings has announced a positive outcome from its FDA RMAT meeting regarding the registrational clinical and CMC strategy for SENTI-202, aimed at treating relapsed/refractory AML. The company also provided significant updates on the efficacy and durability of the SENTI-202 clinical program."
datetime: "2026-05-14T04:40:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286418645.md)
  - [en](https://longbridge.com/en/news/286418645.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286418645.md)
generator: "portal-rs"
---

# Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program | SNTI Stock News

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program | SNTI Stock News

### Related Stocks

- [SNTI.US](https://longbridge.com/en/quote/SNTI.US.md)

## Related News & Research

- [Senti Biosciences unit issues USD 4 million senior secured convertible notes to Celadon Partners SPV 24](https://longbridge.com/en/news/296532896.md)
- [IMMU: Vididencel delivers durable remissions in AML and CML, with broad late-stage clinical expansion](https://longbridge.com/en/news/296462827.md)
- [Matt Phipps Maintains Hold Rating on Incyte as Promising Early KRAS G12D PDAC Data Face Durability and Safety Uncertainties](https://longbridge.com/en/news/296390324.md)
- [Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate](https://longbridge.com/en/news/296689195.md)
- [Moleculin Biotech reports interim MIRACLE trial data showing higher remission rates in relapsed/refractory AML](https://longbridge.com/en/news/295935232.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**